Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and “primed” by tumor-derived exosomes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Immunological strategies to treat pancreatic cancer offer new therapeutic approaches to improve patient outcomes. Understanding alterations in the immune systems of pancreatic cancer patients will likely lead to advances in immunotherapy for the disease. We profiled peripheral blood leukocytes from pancreatic cancer patients (n = 22) and age-matched controls (n = 20) using flow cytometry. Immune profiling of pancreatic cancer patients identified phenotypic changes in various immune cell populations, including a population of immunosuppressive monocytes (CD14+HLA-DRlo/neg), which were shown to be increased in these patients. There was a correlation between the levels of CD14+ monocytes and the levels of CD14+HLA-DRlo/neg monocytes in peripheral blood from pancreatic cancer patients. HLA-DR downregulation of monocytes was shown to occur through pancreatic cancer-derived exosome interactions with monocytes. In an in vitro model, exosomes from patient-derived xenograft cell lines and patient plasma decreased HLA-DR expression on CD14+ monocytes. Additionally, tumor-derived exosomes caused immune suppression in monocytes through altered STAT3 signaling, induction of arginase expression, and reactive oxygen species. These findings provide novel insights into the mechanisms that govern immunosuppression in pancreatic cancer. Understanding monocyte–exosome interactions could lead to novel immunotherapies for this disease.

Original languageEnglish (US)
JournalOncoImmunology
DOIs
StateAccepted/In press - Dec 23 2016

Fingerprint

Exosomes
Immunosuppressive Agents
Pancreatic Neoplasms
Monocytes
Neoplasms
HLA-DR Antigens
Immunotherapy
Arginase
Heterografts
Immunosuppression
Population
Immune System
Reactive Oxygen Species
Flow Cytometry
Leukocytes
Down-Regulation
Cell Line

Keywords

  • Exosomes
  • HLA-DR
  • immune profiling
  • immunosuppression
  • monocytes
  • pancreatic cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

@article{30f42a0ddc3043f8aa7b39b9ed07d87b,
title = "Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and “primed” by tumor-derived exosomes",
abstract = "Immunological strategies to treat pancreatic cancer offer new therapeutic approaches to improve patient outcomes. Understanding alterations in the immune systems of pancreatic cancer patients will likely lead to advances in immunotherapy for the disease. We profiled peripheral blood leukocytes from pancreatic cancer patients (n = 22) and age-matched controls (n = 20) using flow cytometry. Immune profiling of pancreatic cancer patients identified phenotypic changes in various immune cell populations, including a population of immunosuppressive monocytes (CD14+HLA-DRlo/neg), which were shown to be increased in these patients. There was a correlation between the levels of CD14+ monocytes and the levels of CD14+HLA-DRlo/neg monocytes in peripheral blood from pancreatic cancer patients. HLA-DR downregulation of monocytes was shown to occur through pancreatic cancer-derived exosome interactions with monocytes. In an in vitro model, exosomes from patient-derived xenograft cell lines and patient plasma decreased HLA-DR expression on CD14+ monocytes. Additionally, tumor-derived exosomes caused immune suppression in monocytes through altered STAT3 signaling, induction of arginase expression, and reactive oxygen species. These findings provide novel insights into the mechanisms that govern immunosuppression in pancreatic cancer. Understanding monocyte–exosome interactions could lead to novel immunotherapies for this disease.",
keywords = "Exosomes, HLA-DR, immune profiling, immunosuppression, monocytes, pancreatic cancer",
author = "Naureen Javeed and Michael Gustafson and Dutta, {Shamit K.} and Yi Lin and Bamlet, {William R.} and Oberg, {Ann L} and Petersen, {Gloria M} and Chari, {Suresh T} and Dietz, {Allan B} and Debabrata Mukhopadhyay",
year = "2016",
month = "12",
day = "23",
doi = "10.1080/2162402X.2016.1252013",
language = "English (US)",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and “primed” by tumor-derived exosomes

AU - Javeed, Naureen

AU - Gustafson, Michael

AU - Dutta, Shamit K.

AU - Lin, Yi

AU - Bamlet, William R.

AU - Oberg, Ann L

AU - Petersen, Gloria M

AU - Chari, Suresh T

AU - Dietz, Allan B

AU - Mukhopadhyay, Debabrata

PY - 2016/12/23

Y1 - 2016/12/23

N2 - Immunological strategies to treat pancreatic cancer offer new therapeutic approaches to improve patient outcomes. Understanding alterations in the immune systems of pancreatic cancer patients will likely lead to advances in immunotherapy for the disease. We profiled peripheral blood leukocytes from pancreatic cancer patients (n = 22) and age-matched controls (n = 20) using flow cytometry. Immune profiling of pancreatic cancer patients identified phenotypic changes in various immune cell populations, including a population of immunosuppressive monocytes (CD14+HLA-DRlo/neg), which were shown to be increased in these patients. There was a correlation between the levels of CD14+ monocytes and the levels of CD14+HLA-DRlo/neg monocytes in peripheral blood from pancreatic cancer patients. HLA-DR downregulation of monocytes was shown to occur through pancreatic cancer-derived exosome interactions with monocytes. In an in vitro model, exosomes from patient-derived xenograft cell lines and patient plasma decreased HLA-DR expression on CD14+ monocytes. Additionally, tumor-derived exosomes caused immune suppression in monocytes through altered STAT3 signaling, induction of arginase expression, and reactive oxygen species. These findings provide novel insights into the mechanisms that govern immunosuppression in pancreatic cancer. Understanding monocyte–exosome interactions could lead to novel immunotherapies for this disease.

AB - Immunological strategies to treat pancreatic cancer offer new therapeutic approaches to improve patient outcomes. Understanding alterations in the immune systems of pancreatic cancer patients will likely lead to advances in immunotherapy for the disease. We profiled peripheral blood leukocytes from pancreatic cancer patients (n = 22) and age-matched controls (n = 20) using flow cytometry. Immune profiling of pancreatic cancer patients identified phenotypic changes in various immune cell populations, including a population of immunosuppressive monocytes (CD14+HLA-DRlo/neg), which were shown to be increased in these patients. There was a correlation between the levels of CD14+ monocytes and the levels of CD14+HLA-DRlo/neg monocytes in peripheral blood from pancreatic cancer patients. HLA-DR downregulation of monocytes was shown to occur through pancreatic cancer-derived exosome interactions with monocytes. In an in vitro model, exosomes from patient-derived xenograft cell lines and patient plasma decreased HLA-DR expression on CD14+ monocytes. Additionally, tumor-derived exosomes caused immune suppression in monocytes through altered STAT3 signaling, induction of arginase expression, and reactive oxygen species. These findings provide novel insights into the mechanisms that govern immunosuppression in pancreatic cancer. Understanding monocyte–exosome interactions could lead to novel immunotherapies for this disease.

KW - Exosomes

KW - HLA-DR

KW - immune profiling

KW - immunosuppression

KW - monocytes

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85007318951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007318951&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1252013

DO - 10.1080/2162402X.2016.1252013

M3 - Article

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

ER -